AI Article Synopsis
- Patients with female characteristics and dysgenetic gonads that contain testicular tissue are at a higher risk for developing gonadal tumors.
- Current guidelines suggest that the presence of Y chromatin is essential for deciding on preventative gonadectomies in these cases.
- This study involved four patients with similar conditions, and despite inconclusive cytogenetic results and various clinical tests, the authors recommend that all such patients undergo prophylactic gonadectomies followed by hormone replacement therapy.
Article Abstract
Patients with female phenotypes and dysgenetic gonads harboring testicular tissue have a markedly increased risk of developing gonadal tumors. Cytogenetic demonstration of Y chromatin is the currently accepted criterion for performing prophylactic gonadectomies in these women. We studied four patients with dysgenetic gonads containing either testicular tissue or germ cell tumors. All had small sex chromosomal fragments which could not be characterized by conventional cytogenetic studies. Clinical features, DNA replication studies, and immunologic assays of Xga and H-Y antigens failed to correlate consistently with the gonadal histology. We recommend prophylactic gonadectomies and subsequent hormone replacement in all patients with female phenotypes, gonadal dysgenesis, and cytogenetically indeterminate sex chromosomal fragments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0002-9378(84)80113-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Background: Whole genome methylation sequencing (WGMS) in blood identifies extensive differential DNA methylation between persons who are cognitively unimpaired (CU) and those with late-onset dementia due to Alzheimer's disease (AD). Here we investigate differentially methylated positions (DMPs) in persons with mild cognitive impairment (MCI) compared to persons with and without AD.
Method: WGMS data quantified DNA methylation levels at 25,406,945 CpG loci in 382 blood samples from 99 persons with MCI, 109 persons with AD and 174 cognitively unimpaired persons in the Wisconsin Alzheimer's Disease Research Center (WADRC) and the Wisconsin Registry for Alzheimer's Prevention (WRAP).
Biomarkers.
Alzheimers Dement
December 2024
John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.
Background: Sex is an important factor that contributes to both clinical and biological heterogeneity in Alzheimer's disease (AD), but the regulatory mechanisms underlying sex differences in AD are still not well understood. DNA methylation (DNAm) is an epigenetic modification that regulates gene transcription and is known to be involved in AD. However, due to analytical and biological complexity, few previous DNAm studies analyzed the X chromosome, where many genes influencing cognitive abilities and immune functions are located.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Background: Alzheimer's Disease (AD) is a common form of dementia among the elderly with a large percentage of estimated heritability. Conventional polygenic risk analysis only accounts for the linearly combined genomic effects of single nucleotide polymorphisms (SNPs). On the other hand, a deep-learning-based approach is able to uncover nonlinearly associated effects from data with high-dimensional features such as genomics.
View Article and Find Full Text PDFBackground: Obesity, diabetes, hypertension, hyperlipidemia, and depression are relevant Alzheimer's Disease (AD) modifiable risk factors (RFs). However, little is known about how the duration of these conditions, influenced by unmodifiable AD risk factors, such as chromosomal sex and APOE genotype, affects the associated risk. Modeling interactions between patient's temporal and clinical patterns, integrated with the probability of developing AD remains challenging, particularly when considering the multifactorial progression of AD.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Background: Leukocyte telomere length (LTL) serves as a proxy for tissue-specific TL and peripheral immune aging. Its association with aging-related brain endophenotypes, cognitive functioning, and Alzheimer's disease (AD) risk is established, but the underlying molecular mechanisms remain elusive. Investigating LTL's association with AD biomarkers is crucial for identifying its role in brain resilience and disease progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!